(E,E)-N1,N2-Bis(2,6-di­fluoro­benzyl­idene)ethane-1,2-di­amine.

The asymmetric unit of the title compound, C16H12F4N2, comprises half of the potentially bidentate Schiff base ligand, with an inversion centre located at the mid-point of the central C—C bond. The crystal packing is stabilized by inter­molecular C—H⋯N and π–π inter­actions [centroid–centroid distance = 3.6793 (12) Å and inter­planar spacing = 3.4999 (7) Å]

Tau-aggregation inhibitor therapy for Alzheimer's disease

Article Accepted Date: 9 December 2013 Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.Peer reviewedPublisher PD

The study of comets, part 2

Flyby missions and systematic observations of comets are projected for studying comet nuclei and cometary dust tail structures

Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies

Preprin